Premium
Increased Expression of Interleukin‐9, Interleukin‐9 Receptor, and the Calcium‐Activated Chloride Channel hCLCA1 in the Upper Airways of Patients With Cystic Fibrosis
Author(s) -
Hauber HansPeter,
Manoukian John J.,
Nguyen Lily H. P.,
Sobol Steven E.,
Levitt Roy C.,
Holroyd Kenneth J.,
McElvaney Noel G.,
Griffin Siobhan,
Hamid Qutayba
Publication year - 2003
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/00005537-200306000-00022
Subject(s) - mucus , cystic fibrosis , mucous membrane of nose , medicine , mucin , pathology , nasal polyps , biopsy , fibrosis , gastroenterology , biology , ecology
Objectives/Hypothesis Mucus overproduction is commonly found in airway disease in patients with cystic fibrosis. Interleukin‐9 (IL‐9) has been shown to mediate airway hyper‐responsiveness and mucus overproduction. Recently, the calcium‐activated chloride channel hCLCA1 has been described to be upregulated by IL‐9 and has been thought to regulate the expression of soluble gel‐forming mucins. We sought to examine the expression of IL‐9, interleukin‐9 receptor (IL‐9R), and hCLCA1 in the upper airway of patients with cystic fibrosis in comparison to healthy control subjects and to demonstrate the relationship of IL‐9, IL‐9R, and hCLCA1 expression with mucus production. Study Design Prospective design. Methods Biopsy samples from nasal polyps of four patients with cystic fibrosis, nasal mucosa of six patients with cystic fibrosis, sinus mucosa of eight patients with cystic fibrosis, and nasal mucosa of six healthy control subjects were stained with periodic acid‐Schiff (PAS) to identify mucus glycoconjugates. IL‐9, IL‐9R, and hCLCA1 expression was determined by immunocytochemical study. Results We demonstrated significant increases in IL‐9, IL‐9R, and hCLCA1 immunoreactivity in the mucosa of patients with cystic fibrosis compared with that found in control subjects ( P <.05). There were no significant differences between the different locations (nasal polyps, nasal mucosa, and sinus mucosa) in the patient group ( P >.05). We also observed a significant increase in the number of mucus‐producing cells in biopsy specimens from patients with cystic fibrosis in comparison to control subjects. A positive correlation was found between hCLCA1‐positive cells and IL‐9‐positive cells (correlation coefficient [ r ] = 0.79, P <.05) or IL‐9R‐positive cells ( r = 0.92, P <.05). Moreover, a positive correlation was also present between PAS‐positive (mucus‐producing) cells and hCLCA1‐positive cells ( r = 0.64, P <.05) or IL‐9R‐positive cells ( r = 0.64, P <.05). Conclusions Increased expression of IL‐9 and IL‐9R, as well as upregulation of hCLCA1, in mucus‐overproducing epithelium of patients with cystic fibrosis supports the hypothesis that IL‐9 contributes to mucus overproduction in cystic fibrosis. Expression of hCLCA1 may also be responsible, in part, for the overproduction of mucus. These preliminary findings suggest that hCLCA1 might be an interesting new therapeutic target to control mucus overproduction in airway disease in patients with cystic fibrosis.